<?xml version="1.0" encoding="UTF-8"?>
<p>Asunaprevir [
 <xref rid="B192-microorganisms-07-00296" ref-type="bibr">192</xref>] and salidroside [
 <xref rid="B191-microorganisms-07-00296" ref-type="bibr">191</xref>], extracts from 
 <italic>Uncaria tomentosa</italic>, 
 <italic>Norantea brasiliensis</italic> Choisy, 
 <italic>Uncaria guianensis</italic> [
 <xref rid="B196-microorganisms-07-00296" ref-type="bibr">196</xref>,
 <xref rid="B197-microorganisms-07-00296" ref-type="bibr">197</xref>], promyelocytic leukemia protein intrinsic, Ivermectin [
 <xref rid="B198-microorganisms-07-00296" ref-type="bibr">198</xref>], extracts from 
 <italic>Cissampelos pareira Linn</italic> [
 <xref rid="B198-microorganisms-07-00296" ref-type="bibr">198</xref>], and BST2/tetherin [
 <xref rid="B199-microorganisms-07-00296" ref-type="bibr">199</xref>] are some of natural products that have advantages over synthetic drug design [
 <xref rid="B207-microorganisms-07-00296" ref-type="bibr">207</xref>] and also tested as DENV inhibitors. Interferon type I [
 <xref rid="B129-microorganisms-07-00296" ref-type="bibr">129</xref>], human heme oxygenase I, purinergic receptor P2X7 [
 <xref rid="B195-microorganisms-07-00296" ref-type="bibr">195</xref>], and helicase with zinc linger 2 [
 <xref rid="B194-microorganisms-07-00296" ref-type="bibr">194</xref>] are other examples of DENV inhibitors that have been experimentally studied to ascertain their dependence on host immunity, inflammation, pathogenesis of disease, and other disease progress factors (
 <xref rid="microorganisms-07-00296-t001" ref-type="table">Table 1</xref>).
</p>
